{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-000524","form_type":"8-K","ticker":"PRME","cik":"0001894562","company_name":"Prime Medicine, Inc.","filed_at":"2024-01-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:26.259885+00:00","generated_at":"2026-06-07T03:31:31.357487+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Prime Medicine appoints Allan Reine as CFO, effective Jan 17, 2024","bullets":["Allan Reine named CFO and principal financial officer; previously CFO of Foghorn Therapeutics.","Receives $500k base salary, $176k sign-on bonus, 40% target annual bonus, and option grants (600k time-vesting shares + 250k milestone-based shares).","Carman Alenson transitions from interim CFO to SVP Finance and CAO; remains principal accounting officer."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-000524","json":"https://secwatch.observer/filing/0001628280-24-000524.json","markdown":"https://secwatch.observer/filing/0001628280-24-000524.md","text":"https://secwatch.observer/filing/0001628280-24-000524.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1894562/000162828024000524/0001628280-24-000524-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1894562/000162828024000524/prme-20240104.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T03:31:31.357487+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"228a242e84","claim":"Allan Reine was appointed as Chief Financial Officer at Prime Medicine, Inc..","evidence_excerpt":"On January 4, 2024, the Board of Directors (the “Board”) of Prime Medicine, Inc. (the “Company”) appointed Allan Reine as the Chief Financial Officer and the principal financial officer of the Company effective as of January 17, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1894562/000162828024000524/0001628280-24-000524-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}